DOCSLIB.ORG

What Science Can Do Can Science What

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What Science Can Do Can Science What What science can do AstraZeneca Annual Report and Form 20-F Information 2017 AstraZeneca Annual Report and 20-F Form Information 2017 Welcome We are a global, science-led biopharmaceutical business and in this Annual Report we report on the progress we made in 2017 in pushing the boundaries of science to deliver life-changing medicines. can Science Expand treatment options Oncology | From page 48 Understand disease Cardiovascular & Metabolic Diseases | From page 52 Transform outcomes Respiratory | From page 56 Front cover and inside Important information for readers of this Annual Report Directors’ Report front cover image: For more information in relation to the inclusion of The following sections make up the Directors’ Report, Upstream intervention in Reported performance, Core financial measures and which has been prepared in accordance with the the inflammatory cascade. constant exchange rate (CER) growth rates as used requirements of the Companies Act 2006: in this Annual Report, please see the Financial Review When lungs are stressed by on page 66. > Chairman’s Statement allergens, pathogens or irritants, > Chief Executive Officer’s Review epithelial cells produce Definitions > Business Review cytokines that trigger multiple The Glossary and the Market definitions table from > Therapy Area Review downstream inflammatory page 235 are intended to provide a useful guide to terms > Financial Review: Financial risk management pathways in the lungs. and AstraZeneca’s definitions of markets, as well as to > Corporate Governance: including the Audit Committee AstraZeneca is researching acronyms and abbreviations, used in this Annual Report. Report and Corporate Governance Report antibodies that bind to these > Directors’ Responsibility Statement upstream epithelial cytokines Use of terms > Development Pipeline to prevent a range of In this Annual Report, unless the context otherwise > Sustainability: supplementary information inflammatory responses. requires, ‘AstraZeneca’, ‘the Group’, ‘we’, ‘us’ and ‘our’ > Shareholder Information refer to AstraZeneca PLC and its consolidated entities. Strategic Report Cautionary statement regarding forward‑looking statements The following sections make up the Strategic Report, A cautionary statement regarding forward-looking which has been prepared in accordance with the statements and other essential information relating requirements of the Companies Act 2006: to this Annual Report can be found on page 240. > AstraZeneca at a glance > Chairman’s Statement > Chief Executive Officer’s Review > Marketplace > Business model and life-cycle of a medicine > Strategy and Key Performance Indicators > Business Review > Therapy Area Review > Risk Overview > Financial Review Strategic Report Strategic Report Contents AstraZeneca at a glance 2 Chairman’s Statement 4 Chief Executive Officer’s Review 5 Marketplace 8 Business model and life-cycle of a medicine 14 Strategy and Key Performance Indicators 17 Business Review 22 Therapy Area Review 46 > Oncology 48 > Cardiovascular & Metabolic Diseases 52 > Respiratory 56 > Other Disease Areas 60 Risk Overview 63 Financial highlights Financial Review 66 Total Revenue* Net cash flow from operating activities down 2% to $22,465 million at actual down 14% at actual rate of exchange Corporate Governance rate of exchange (down 2% at CER), to $3,578 million Corporate Governance comprising Product Sales of $20,152 million Chairman’s Introduction 86 and Externalisation Revenue of $2,313 million Corporate Governance Overview 87 2017 $22,465m 2017 $3,578m Board of Directors 88 2016 $23,002m 2016 $4,145m Senior Executive Team 90 2015 $24,708m 2015 $3,324m Corporate Governance Report 92 Audit Committee Report 100 $22.5bn $3.6bn Directors’ Remuneration Report 105 Reported operating profit Core operating profit down 25% at actual rate of exchange up 2% at actual rate of exchange to $3,677 million (down 28% at CER) to $6,855 million (unchanged at CER) 2017 $3,677m 2017 $6,855m 2016 $4,902m 2016 $6,721m 2015 $4,114m 2015 $6,902m Financial Statements Financial $3.7bn $6.9bn Financial Statements Auditors’ Report 129 Consolidated Statements 135 Group Accounting Policies 139 Reported EPS Core EPS Notes to the Group for the full year down 14% at actual rate for the full year down 1% at actual rate Financial Statements 145 of exchange to $2.37 (down 15% at CER) of exchange to $4.28 (down 2% at CER) Group Subsidiaries and Holdings 190 2017 $2.37 2017 $4.28 Company Statements 194 2016 $2.77 2016 $4.31 Company Accounting Policies 196 2015 $2.23 2015 $4.26 Notes to the Company Financial Statements 197 $2.37 $4.28 Group Financial Record 199 Financial Review from page 66. * As detailed on page 140, Total Revenue consists of Product Sales and Externalisation Revenue. Additional Information Additional Information For more information Development Pipeline 202 within this Annual Report Patent Expiries of Key Marketed Products 208 For more information see Risk 210 www.astrazeneca.com Geographical Review 221 Sustainability: supplementary information 227 Shareholder Information 228 Trade Marks 234 Glossary 235 Index 239 This Annual Report is also available on our website, www.astrazeneca.com/annualreport2017 AstraZeneca Annual Report & Form 20-F Information 2017 / Contents 1 AstraZeneca A global biopharmaceutical business at a glance delivering medicines to patients through innovative science and excellence in development and commercialisation. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We want to be valued and trusted by our stakeholders as a source of great medicines over the long term. Our strategic priorities Reflect how we are 1. Achieve Scientific Leadership working to achieve 2. Return to Growth our Purpose 3. Be a Great Place to Work A science-led Distinctive R&D innovation strategy capabilities: 11 Small molecules, ne molecular entities s in ase III/ Strategy and Key Performance oligonucleotides pivotal ase II or uner regulator reiew Indicators from page 17. and other emerging covering 1 inications drug platforms, as well as biologic 2017 11 medicines, including 201 12 immunotherapies, 201 1 and innovative 201 1 delivery devices Broad R&D platform in Oncology Cardiovascular & Respiratory three main areas Our ambition is to Metabolic Diseases We aim to transform We are also eliminate cancer We are following the the treatment of selectively active Achieve Scientific Leadership as a cause of death science to transform respiratory disease in the areas of from page 23 and Therapy through scientific how cardiovascular, with our growing autoimmunity, Area Review from page 46. discovery and renal and metabolic portfolio of medicines neuroscience collaborations. diseases are and scientific and infection We seek to achieve understood, interact research targeting this by means of and impact one disease modification exploiting the another power of four scientific platforms Portfolio of specialty and Oncology Cardiovascular & Respiratory Other Disease Areas primary care products Metabolic Diseases (Product Sales) $4,024m $7,266m $4,706m $4,156m 20% of total 36% of total 23% of total 21% of total 2016: $3,383m 2016: $8,116m 2016: $4,753m 2016: $5,067m 2015: $2,825m 2015: $9,489m 2015: $4,987m 2015: $6,340m Tagrisso sales up 126% Brilinta sales of $1,079 Symbicort sales of Nexium sales down 4% (126% at CER) and approved million, up 29% (29% at $2,803 million, down 6% (3% at CER) to $1,952 million in more than 60 markets CER) and Forxiga sales (6% at CER) Sales of Synagis up 1% Iressa sales of $528 million, of $1,074 million, up 29% Sales of Pulmicort up (1% at CER) to $687 million (28% at CER) up 3% (3% at CER); Lynparza 11% (12% at CER) at Seroquel XR sales of $332 sales of $297 million, up 36% Sales of Onglyza were $1,176 million million, down 55% (55% (35% at CER) down by 15% (16% at Fasenra approved in the at CER) CER) to $611 million Imfinzi launched in the US in US in November FluMist/Fluenz sales of May and sales of $19 million; Legacy sales: Crestor $78 million, down 25% Calquence launched in the down 30% (30% at CER) (28% at CER) US in October and sales of to $2,365 million $3 million 2 AstraZeneca Annual Report & Form 20-F Information 2017 / Strategic Report Strategic Report Oncology. See page 48 Cardiovascular & Metabolic Diseases. See page 52 Respiratory. See page 56 Global commercial US Emerging Markets Europe Established presence, with strength Rest of World in Emerging Markets (Product Sales) $6,169m $6,149m $4,753m $3,081m 31% of total 30% of total 24% of total 15% of total 2016: $7,365m 2016: $5,794m 2016: $5,064m 2016: $3,096m 2015: $9,474m 2015: $5,822m 2015: $5,323m 2015: $3,022m Commercial Highlights: Emerging Markets: Sales New CVMD: Sales growth Japan: 1% growth in sales New Oncology: Sales Growth Platforms grew growth of 6% (8% at CER), of 9% (9% at CER). Strong (4% at CER), underpinned growth of 98% (98% at in line with long-term performances from Farxiga by the growth of Tagrisso CER). Sales of Tagrisso by 5% (6% at CER) in 2017 ambitions. China sales in and Brilinta, with sales and Forxiga, partly mitigated reached $955 million to and represented 68% of the year grew by 12% (15% exceeding $1 billion in 2017 by the impact of the entry become AstraZeneca’s Total Revenue at CER), supported by the Respiratory: Sales declined of generic competition to largest-selling Oncology launches of new medicines by 1% (1% at CER). Sales of Crestor in the second half medicine of the year Return to Growth from page 26. Symbicort declined by 6% (6% at CER) and Pulmicort sales rose by 11% (12% at CER) Our talented employees: Committed to achieving 61,100 our Purpose in a sustainable employees 3 way and upholding our 2016: 59,700 6 Values by fostering a strong 2015: 61,500 1 AstraZeneca culture Strategic R cetre 5 8 arige 4 2 7 aiterrg S Be a Great Place to Work from page 34.
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives
    International Journal of Molecular Sciences Review Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives In-Ho Kim 1 and Hyo-Jin Lee 2,* 1 Department of Internal Medicine, Division of Medical Oncology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul 06591, Korea; [email protected] 2 Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon 35015, Korea * Correspondence: [email protected]; Tel.: +82-42-280-8369; Fax: +82-42-257-5753 Abstract: Radical cystectomy is the primary treatment for muscle-invasive bladder cancer; however, approximately 50% of patients develop metastatic disease within 2 years of diagnosis, which re- sults in dismal prognosis. Therefore, systemic treatment is important to improve the prognosis of muscle-invasive bladder cancer. Currently, several guidelines recommend cisplatin-based neoad- juvant chemotherapy before radical cystectomy, and adjuvant chemotherapy is recommended in patients who have not received neoadjuvant chemotherapy. Immune checkpoint inhibitors have recently become the standard treatment option for metastatic urothelial carcinoma. Owing to their clinical benefits, several immune checkpoint inhibitors, with or without other agents (including other immunotherapy, cytotoxic chemotherapy, and emerging agents such as antibody drug conjugates), are being extensively investigated in perioperative settings. Several studies for perioperative im- munotherapy have shown that immune checkpoint inhibitors have promising efficacy with relatively low toxicity, and have explored the predictive molecular biomarkers. Herein, we review the current evidence and discuss the future perspectives of perioperative systemic treatment for muscle-invasive Citation: Kim, I.-H.; Lee, H.-J. bladder cancer. Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Keywords: bladder cancer; immunotherapy; perioperative systemic treatment Current Evidence and Future Perspectives.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • 2018 Medicines in Development for Cancer
    2018 Medicines in Development for Cancer Bladder Cancer Product Name Sponsor Indication Development Phase ABI-009 AADi Bioscience non-muscle invasive bladder cancer Phase I/II (nab-rapamycin/mTOR inhibitor) Los Angeles, CA www.aadibio.com ALT-801 Altor BioScience non-muscle invasive bladder cancer Phase I/II (tumor antigen-specific T-cell Miramar, FL www.altorbioscience.com receptor linked to IL-2) NantKwest Culver City, CA ALT-803 Altor BioScience non-muscle invasive bladder cancer Phase II (IL-15 superagonist protein complex) Miramar, FL (BCG naïve) (Fast Track), www.altorbioscience.com NantKwest non-muscle invasive bladder cancer Culver City, CA (BCG unresponsive) (Fast Track) B-701 BioClin Therapeutics 2L locally advanced or metastatic Phase I/II (anti-FGFR3 mAb) San Ramon, CA bladder cancer www.bioclintherapeutics.com Bavencio® EMD Serono 1L urothelial cancer Phase III avelumab Rockland, MA www.emdserono.com (anti-PD-L1 inhibitor) Pfizer www.pfizer.com New York, NY BC-819 BioCanCell Therapeutics non-muscle invasive bladder cancer Phase II (gene therapy) Cambridge, MA (Fast Track) www.biocancell.com Medicines in Development: Cancer ǀ 2018 1 Bladder Cancer Product Name Sponsor Indication Development Phase Capzola® Spectrum Pharmaceuticals non-muscle invasive bladder cancer application submitted apaziquone Henderson, NV (Fast Track) www.sppirx.com Cavatak® Viralytics bladder cancer (+pembrolizumab) Phase I coxsackievirus Sydney, Australia www.viralytics.com CG0070 Cold Genesys non-muscle invasive bladder cancer Phase II (oncolytic immunotherapy)
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • H1 2020 Results
    H1 2020 results Roadshows and conferences Forward-looking statements disclaimer In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements
    [Show full text]
  • H1 2021 Results Clinical Trials Appendix PDF 2769KB
    Clinical trials appendix Q2 2021 results update Movement since Q1 2021 update New to Phase I New to Phase II New to Pivotal trial New to registration NME NME NME AZD1402# AZD2816¶# (next generation COVID-19 vaccine) tezepelumab# NAVIGATOR [US, EU & JP] 1 Inhaled IL4Ra asthma SARS-CoV-2 prevention of COVID-19 TSLP mAb severe, uncontrolled asthma AZD9977 + Farxiga Additional indication Lifecycle management # MCR + SGLT2 inhibitor heart failure with CKD capivasertib + fulvestrant + palbociclib CAPItello-292 Fasenra# OSTRO [US] 1 AKT inhibitor + fulvestrant + CDK4/6 inhibitor 1st- line triplet in early IL5R mAb nasal polyps zibotentan + Farxiga3 ZENITH-CKD relapse/ET resistant locally advanced (inoperable) or metastatic breast cancer ETA antagonist + SGLT2 CKD Lifecycle Management Enhertu# DESTINY-Breast09 HER2 targeting antibody drug conjugate 1st-line HER2-postitive breast cancer Enhertu# DESTINY-Gastric04 HER2 targeting antibody drug conjugate 2nd-line HER2-positive gastric cancer Lokelma DIALIZE-Outcomes potassium binder CV outcomes in patients on chronic hemodialysis with hyperkalemia tezepelumab# WAYPOINT TSLP mAb nasal polyposis Removed from Phase I Removed from Phase II Removed from Phase III Removed from registration Additional indication Lifecycle management Lifecycle management Imfinzi + Lynparza# BAYOU Lynparza# SOLO-3 Farxiga3 DAPA-CKD [US] 2 PD-L1 mAb + PARP inhibitor 1st-line unresectable PARP inhibitor gBRCA PSR ovarian cancer SGLT2 inhibitor renal outcomes and CV mortality in stage IV bladder cancer patients with CKD tezepelumab#
    [Show full text]
  • Astrazeneca Deals – Key Highlights
    COMPANY OVERVIEW NOVEMBER 2020 NASDAQ: IPHA EURONEXT PARIS: IPH Forward Looking Statements This document has been prepared by Innate Pharma S.A. (the “Company”) solely for This presentation discusses product candidates that are under clinical development the purposes of a presentation to investors concerning the Company. This document and which have not yet been approved for marketing by the U.S. Food and Drug is not to be reproduced by any person, nor to be distributed. Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such This document contains forward-looking statements. The use of certain words, product candidates are being studied. including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its The information contained herein has not been independently verified. No expectations are based on reasonable assumptions, these forward-looking representation, warranty or undertaking, express or implied, is made as to, and no statements are subject to various risks and uncertainties, which could cause the reliance should be placed on, the fairness, accuracy, completeness or correctness of Company’s actual results or financial condition to differ materially from those the information or opinions contained herein. The Company is under no obligation to anticipated. These risks and uncertainties include, among other things, the keep current the information contained in this presentation and any opinion uncertainties inherent in research and development, including related to safety, expressed is subject to change without notice. progression of and results from its ongoing and planned clinical trials and preclinical The Company shall not bear any liability whatsoever for any loss arising from any use studies, review and approvals by regulatory authorities of its product candidates, the of this document or its contents or otherwise arising in connection therewith.
    [Show full text]
  • Filed by Astrazeneca PLC This Communication Is Filed Pursuant to Rule 425 Under the United States Securities Act of 1933 Subject Company: Alexion Pharmaceuticals, Inc
    Filed by AstraZeneca PLC This communication is filed pursuant to Rule 425 under the United States Securities Act of 1933 Subject Company: Alexion Pharmaceuticals, Inc. (Commission File No. 000-27756) Date: February 11, 2021 The following presentation was made available by AstraZeneca PLC on its website on February 11, 2021 FY2020results Conference call and webcast for investors and analysts 11 February 2021 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions
    [Show full text]
  • A61K9/51 (2006.01) — with International Search Report (Art
    ) ( 2 (51) International Patent Classification: Published: A61K9/51 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US20 19/033 875 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (22) International Filing Date: 24 May 2019 (24.05.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/676,169 24 May 2018 (24.05.2018) US (71) Applicant: ELEKTROFI, INC. [US/US]; 75 Kneeland Street, 14th Floor, Boston, MA 021 11 (US). (72) Inventors: COFFMAN, Chase; 86 Worcester Street, Unit 3, Boston, MA 021 18 (US). CHARLES, Lyndon; 600 Main St Apt 3, Medford, MA 02155 (US). BROWN, Paul; 156 W 6th St, Unit 2, Boston, MA 02127 (US). DADON, Daniel, Benjamin; 2 Garden Court, Apt. 1, Cambridge, MA 02138 (US). LIU, Lisa; 111 Bartlett Street, Apt 2, Somerville, MA 02145 (US). SHADBAR, Sadiqua; 1307 Commonwealth Avenue, Apt 9, Allston, MA 02135 (US). SUDRIK, Chaitanya; 7 1 Elm Street, Apartment #2, Cam¬ bridge, MA 02139 (US). (74) Agent: BELLIVEAU, Michael J. et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 021 10 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
    Journal of Clinical Medicine Review The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies Andres Garcia-Sampedro , Gabriella Gaggia , Alexander Ney , Ismahan Mahamed and Pilar Acedo * Institute for Liver and Digestive Health, Royal Free Hospital Campus, University College London, London NW3 2QG, UK; [email protected] (A.G.-S.); [email protected] (G.G.); [email protected] (A.N.); [email protected] (I.M.) * Correspondence: [email protected] Abstract: Pancreatic cancer is a devastating disease with very poor prognosis. Currently, surgery followed by adjuvant chemotherapy represents the only curative option which, unfortunately, is only available for a small group of patients. The majority of pancreatic cancer cases are diagnosed at advanced or metastatic stage when surgical resection is not possible and treatment options are lim- ited. Thus, novel and more effective therapeutic strategies are urgently needed. Molecular profiling together with targeted therapies against key hallmarks of pancreatic cancer appear as a promising ap- proach that could overcome the limitations of conventional chemo- and radio-therapy. In this review, we focus on the latest personalised and multimodal targeted therapies currently undergoing phase II or III clinical trials. We discuss the most promising findings of agents targeting surface receptors, angiogenesis, DNA damage and cell cycle arrest, key signalling pathways, immunotherapies, and the tumour microenvironment. Keywords: pancreatic cancer; PDAC; clinical trials; targeted therapies; immunotherapy; cancer vaccines; tumour microenvironment Citation: Garcia-Sampedro, A.; Gaggia, G.; Ney, A.; Mahamed, I.; Acedo, P. The State-of-the-Art of Phase II/III Clinical Trials for 1.
    [Show full text]